Intra-Cellular Therapies Inc
NASDAQ:ITCI
Net Margin
Intra-Cellular Therapies Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | US |
| Market Cap | 6.4B USD |
| Net Margin |
-22%
|
| Country | JP |
| Market Cap | 776 550.9T JPY |
| Net Margin |
-79%
|
| Country | US |
| Market Cap | 744.3B USD |
| Net Margin |
17%
|
| Country | DK |
| Market Cap | 4.1T DKK |
| Net Margin |
37%
|
| Country | UK |
| Market Cap | 440.4B GBP |
| Net Margin |
-4%
|
| Country | US |
| Market Cap | 364.1B USD |
| Net Margin |
45%
|
| Country | US |
| Market Cap | 331.8B USD |
| Net Margin |
4%
|
| Country | UK |
| Market Cap | 189.2B GBP |
| Net Margin |
13%
|
| Country | CH |
| Market Cap | 188.1B CHF |
| Net Margin |
20%
|
| Country | CH |
| Market Cap | 182.7B CHF |
| Net Margin |
30%
|
| Country | US |
| Market Cap | 161.7B USD |
| Net Margin |
-1%
|
Profitability Report
View the profitability report to see the full profitability analysis for Intra-Cellular Therapies Inc.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Intra-Cellular Therapies Inc's most recent financial statements, the company has Net Margin of -21.6%.
You don't have any saved screeners yet
